Evidence map›Paper›PMID 37318626›Full record

ArticleAmino acids2023

Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI

Ayca Ece Nezir, Zeynep Busra Bolat, Naile Ozturk, Polen Kocak, Ebru Zemheri, Sevgi Gulyuz, Umut Ugur Ozkose, Ozgur Yilmaz, Imran Vural, Asuman Bozkır and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Amino acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. PEtOx-DOPE nanoliposomes functionalized with peptide 563 in targetedTurkish journal of biology = Turk biyoloji dergisi · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ayca Ece NezirDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Inonu Mahallesi, Kayisdagi Caddesi, Atasehir, 34755, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8229-1865
Zeynep Busra BolatDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Inonu Mahallesi, Kayisdagi Caddesi, Atasehir, 34755, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-9216-6336
Naile OzturkDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.ORCID http://orcid.org/0000-0002-7617-8433
Polen KocakDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Inonu Mahallesi, Kayisdagi Caddesi, Atasehir, 34755, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-4493-1061
Ebru ZemheriDepartment of Pathology, Umraniye Training and Research Hospital, University of Health Sciences, Umraniye, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-0247-0332
Sevgi GulyuzMaterials Institute, Marmara Research Center, TUBITAK, Gebze, Turkey.ORCID http://orcid.org/0000-0002-2576-3085
Umut Ugur OzkoseMaterials Institute, Marmara Research Center, TUBITAK, Gebze, Turkey.ORCID http://orcid.org/0000-0003-4807-6322
Ozgur YilmazMaterials Institute, Marmara Research Center, TUBITAK, Gebze, Turkey.ORCID http://orcid.org/0000-0003-3892-2775
Imran VuralDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1627-3834
Asuman BozkırDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Yeni Mahalle, 06560, Ankara, Turkey.ORCID http://orcid.org/0000-0002-2782-3280
Fikrettin SahinDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Inonu Mahallesi, Kayisdagi Caddesi, Atasehir, 34755, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-1503-5567
Dilek TelciDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Inonu Mahallesi, Kayisdagi Caddesi, Atasehir, 34755, Istanbul, Turkey. dilek.telci@yeditepe.edu.tr.ORCID http://orcid.org/0000-0002-2793-6533

Funding

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 213M725Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 213M726Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 213M728
6 · The paper itself

Abstract

Prostate cancer is a global disease that negatively affects the quality of life. Although various strategies against prostate cancer have been developed, only a few achieved tumor-specific targeting. Therefore, a special emphasis has been placed on the treatment of cancer using nano-carrier-encapsulated chemotherapeutic agents conjugated with tumor-homing peptides. The targeting strategy coupling the drugs with nanotechnology helps to overcome the most common barriers, such as high toxicity and side effects. Prostate-specific membrane antigen has emerged as a promising target molecule for prostate cancer and shown to be targeted with high affinity by GRFLTGGTGRLLRIS peptide known as peptide 563 (P563). Here, we aimed to assess the in vitro and in vivo targeting efficiency, safety, and efficacy of P563-conjugated, docetaxel (DTX)-loaded polymeric micelle nanoparticles (P563-PEtOx-co-PEI

Indexed as

Antineoplastic AgentsProstatic NeoplasmsAnimalsCell Line, TumorDocetaxelHumansMaleMiceMicellesPeptidesPolymersQuality of LifeTaxoidsAntineoplastic AgentsDocetaxelMicellesPeptidesPolymersTaxoidsDocetaxelDrug deliveryPeptide 563Polymeric micelleProstate cancerTargeted therapy

Identifiers

PMID37318626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.